Muscle-invasive Bladder Cancer
📧 Sign up to get email alerts when something new happens for Muscle-invasive Bladder Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-06-17Clinical Trial Update: Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer [Phase 3]
Phase 3 clinical trial investigating pembrolizumab (MK-3475) after surgery for localized muscle-invasive bladder cancer and locally advanced…
-
CLINICAL_TRIALS trial_result · 2026-06-05Clinical Trial Update: A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder [Phase 3]
Phase 3 trial comparing TAR-200 plus cetrelimab versus concurrent chemoradiotherapy in muscle-invasive bladder cancer is active but not recr…
-
CLINICAL_TRIALS trial_result · 2026-06-04Clinical Trial Update: Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin [Phase 3]
Phase 3 trial investigating durvalumab with tremelimumab and enfortumab vedotin or durvalumab with enfortumab vedotin for muscle invasive bl…
-
CLINICAL_TRIALS trial_result · 2026-04-28Clinical Trial Update: Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) [Phase 3]
Phase 3 trial evaluating pembrolizumab with chemoradiotherapy versus chemoradiotherapy alone in muscle-invasive bladder cancer.
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer [Phase 2]
Phase 2 trial update for sacituzumab govitecan used before radical cystectomy in muscle invasive bladder cancer; the study is terminated wit…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2) [Phase 3]
Phase 3 NIAGARA-2 trial evaluates perioperative durvalumab with neoadjuvant ddMVAC or gemcitabine/cisplatin in muscle-invasive bladder cance…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial [Phase 2]
Phase 2 BRIGHT trial combines immunotherapy with radiation therapy to potentially avoid bladder removal after shrinking muscle-invasive blad…
-
CLINICAL_TRIALS withdrawal · 2026-04-21Clinical Trial Update: Daily Online Adaptive Short-Course Radiation Therapy and Concurrent Chemotherapy for Muscle-Invasive Bladder Cancer [NA]
A clinical trial evaluating daily online adaptive short-course radiation therapy with concurrent chemotherapy for muscle-invasive bladder ca…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer [Phase 3]
A Phase 3 trial compares chemotherapy alone versus chemotherapy plus nivolumab or nivolumab with BMS-986205, followed by continued nivolumab…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder [Phase 2]
Phase 2 clinical trial evaluating enfortumab vedotin in combination with pembrolizumab for muscle-invasive bladder cancer to help preserve t…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin [Phase 3]
Phase 3 trial evaluating durvalumab + tremelimumab + enfortumab vedotin versus durvalumab + enfortumab vedotin in cisplatin-ineligible or ci…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Tumor Budding and T1 Substaging in Urothelial Bladder Cancer
A clinical trial update focusing on tumor budding and T1 sub-staging in urothelial bladder cancer; recruitment is not yet started.
-
CLINICAL_TRIALS other · 2026-04-13Clinical Trial Update: Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer [Phase 3]
A Phase 3 clinical trial is evaluating chemoradiotherapy with or without atezolizumab for localized muscle-invasive bladder cancer; the stud…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder [Phase 3]
Phase 3 study evaluating TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy for muscle-invasive bladder cancer; the …
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Immune-Stromal Landscape in Muscle-Invasive Bladder Cancer
A ClinicalTrials.gov entry describes a study evaluating the immune-stromal landscape in muscle-invasive bladder cancer, sponsored by Assiut …
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations [Phase 2]
Phase 2 clinical trial evaluating gemcitabine and cisplatin without cystectomy for muscle-invasive bladder cancer with selected genetic alte…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study [Phase 3]
A Phase 3 trial (ARCHER) compares shorter-duration radiation therapy plus standard chemotherapy to standard radiation therapy with chemother…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Pembrolizumab in Muscle-invasive Bladder Cancer [Phase 2]
A Phase 2 clinical trial evaluating pembrolizumab for muscle-invasive bladder cancer and urothelial carcinoma is currently active but not re…
-
CLINICAL_TRIALS trial_result · 2026-03-27Clinical Trial Update: Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer [Phase 2]
Phase 2 study evaluating sacituzumab govitecan as neoadjuvant therapy before radical cystectomy for muscle-invasive bladder cancer has compl…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy [Phase 3]
This Phase 3 trial evaluates atezolizumab versus placebo as adjuvant therapy in high-risk muscle-invasive bladder cancer patients who are ct…
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC [Phase 2]
A Phase 2 clinical trial is evaluating probiotics combined with targeted therapy and immunotherapy in a bladder-preserving approach for musc…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer [Phase 2]
A Phase 2 clinical trial evaluating preoperative immunotherapy combined with sacituzumab govitecan for muscle-invasive bladder cancer is cur…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial [Phase 2]
Phase 2 trial update for a neoadjuvant intravesical therapy combining nadofaragene firadenovec with gemcitabine, cisplatin, and durvalumab i…
-
CLINICAL_TRIALS trial_result · 2026-03-13Clinical Trial Update: Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer [Phase 1]
A phase 1 clinical trial is evaluating adaptive radiotherapy with Sacituzumab Govitecan for localized or muscle-invasive bladder cancer. The…
-
CLINICAL_TRIALS research · 2026-03-06Clinical Trial Update: Conventionally Fractionated Adaptive Radiation Therapy of Bladder Cancer an Individualized Approach [NA]
A clinical trial update on an individualized, conventionally fractionated adaptive radiation therapy approach for bladder cancer, with the s…